Upgrade to SI Premium - Free Trial

Volitionrx Limited (VNRX)

1.39 0.00 (0.00%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (8/19/26)

Latest Headlines

Form 8-K VOLITIONRX LTD For: Jun 07 June 10, 2026 6:02 AM - SEC Filing Form 424B5 VOLITIONRX LTD June 9, 2026 9:26 AM - SEC Filing VolitionRx prices $4.6 million stock offering at $1.55 per share June 7, 2026 6:30 PM - StreetInsider VolitionRx Announces Pricing of $4.6 Million Public Offering June 7, 2026 6:30 PM - PR NewsWire Form 424B5 VOLITIONRX LTD June 5, 2026 4:02 PM - SEC Filing VolitionRx files patent for Ebola test using Nu.Q technology June 3, 2026 8:13 AM - StreetInsider VolitionRx Files New Patent Protecting its Nu.Q® NETs Test for Ebola Triage and Treatment Monitoring June 3, 2026 8:12 AM - PR NewsWire Form DEF 14A VOLITIONRX LTD For: Jul 17 June 2, 2026 4:22 PM - SEC Filing Benchmark Reiterates Hold Rating on VolitionRX (VNRX) June 2, 2026 8:42 AM - StreetInsider VolitionRx reports 300% Q1 revenue growth, submits feline cancer test May 27, 2026 8:17 AM - StreetInsider VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution Across $27+ Billion Total Addressable Markets May 27, 2026 8:17 AM - PR NewsWire Form 8-K VOLITIONRX LTD For: May 21 May 22, 2026 5:00 PM - SEC Filing VolitionRX (VNRX) PT Raised to $24 at Jones Trading May 18, 2026 4:02 PM - StreetInsider Form 8-K VOLITIONRX LTD For: May 12 May 15, 2026 4:46 PM - SEC Filing Form SCHEDULE 13G/A VOLITIONRX LTD Filed by: Lagoda Investment Management, L.P. May 15, 2026 4:08 PM - SEC Filing Volitionrx Limited (VNRX) Misses Q1 EPS by 93c May 15, 2026 9:31 AM - StreetInsider Form 10-Q VOLITIONRX LTD For: Mar 31 May 14, 2026 4:22 PM - SEC Filing Form 8-K VOLITIONRX LTD For: May 14 May 14, 2026 4:19 PM - SEC Filing VolitionRx Limited Announces First Quarter 2026 Financial Results and Business Update May 14, 2026 4:10 PM - PR NewsWire Form PRE 14A VOLITIONRX LTD For: May 12 May 13, 2026 4:15 PM - SEC Filing VolitionRx Limited Schedules First Quarter 2026 Earnings Conference Call and Business Update May 11, 2026 8:19 AM - PR NewsWire VolitionRx Announces Submission of Manuscript for Nu.Q® Vet Cancer Test in Cats May 6, 2026 8:17 AM - PR NewsWire Form 10-K/A VOLITIONRX LTD For: Dec 31 April 30, 2026 4:46 PM - SEC Filing Volition Announces Breakthrough Finger-Prick Detection of Nucleosomes; Expanding Global Market Potential for Sepsis Testing April 29, 2026 8:17 AM - PR NewsWire Form 8-K VOLITIONRX LTD For: Apr 28 April 28, 2026 5:01 PM - SEC Filing Form 8-K VOLITIONRX LTD For: Apr 23 April 23, 2026 8:46 AM - SEC Filing VolitionRx receives NYSE American approval for compliance plan April 23, 2026 8:12 AM - StreetInsider VolitionRx Announces Acceptance of Compliance Plan by NYSE American April 23, 2026 8:12 AM - PR NewsWire Form 8-K VOLITIONRX LTD For: Apr 17 April 21, 2026 9:08 AM - SEC Filing VolitionRx launches online shop for recombinant nucleosome products April 20, 2026 7:30 AM - StreetInsider Volition Launches rNuQ™ Webshop Broadening Product Range April 20, 2026 7:30 AM - PR NewsWire D. Boral Capital Downgrades VolitionRX (VNRX) to Hold April 20, 2026 7:02 AM - StreetInsider Form 8-K VOLITIONRX LTD For: Apr 17 April 17, 2026 5:01 PM - SEC Filing VolitionRX (VNRX) PT Lowered to $1 at H.C. Wainwright April 6, 2026 6:51 AM - StreetInsider Benchmark Reiterates Hold Rating on VolitionRX (VNRX) April 2, 2026 8:40 AM - StreetInsider Form 8-K VOLITIONRX LTD For: Mar 31 April 1, 2026 4:31 PM - SEC Filing Form 10-K VOLITIONRX LTD For: Dec 31 March 31, 2026 4:15 PM - SEC Filing Form 8-K VOLITIONRX LTD For: Mar 31 March 31, 2026 4:13 PM - SEC Filing VolitionRx Limited Announces Full Fiscal Year 2025 Financial Results and Business Update March 31, 2026 4:05 PM - PR NewsWire VolitionRx secures $2.3 million non-dilutive funding from Belgium March 31, 2026 8:16 AM - StreetInsider VolitionRx Secures EUR 2.0 Million of Non-Dilutive Funding from Regional Government Agencies in Belgium March 31, 2026 8:16 AM - PR NewsWire VolitionRx study finds elevated nucleosome levels in trauma patients March 30, 2026 8:13 AM - StreetInsider Volition Announces Mayo Clinic Study Demonstrates Nu.Q® Concentrations are Elevated in Trauma Patients March 30, 2026 8:13 AM - PR NewsWire Volition Announces Abstract Demonstrating Risk Stratification in Lung Cancer Presented at the European Lung Cancer Conference March 26, 2026 8:17 AM - PR NewsWire VolitionRx Limited Schedules Full Fiscal Year 2025 Earnings Conference Call and Business Update March 25, 2026 4:12 PM - PR NewsWire Volition reports 95% detection rate for early-stage cancers March 25, 2026 8:17 AM - StreetInsider Volition Announces Detection of Over 95% of Early-Stage Cancers March 25, 2026 8:17 AM - PR NewsWire Form 4 VOLITIONRX LTD For: Mar 17 Filed by: Forterre Gael March 19, 2026 4:32 PM - SEC Filing Form 4 VOLITIONRX LTD For: Mar 17 Filed by: Rootsaert Rodney Gerard March 19, 2026 4:32 PM - SEC Filing Form 4 VOLITIONRX LTD For: Mar 17 Filed by: Micallef Jacob Vincent March 19, 2026 4:31 PM - SEC Filing Form 4 VOLITIONRX LTD For: Mar 17 Filed by: Plummer Nicholas March 19, 2026 4:30 PM - SEC Filing Volition Reports Breakthrough in Liquid Biopsy: Achievement of over 99% Purity in Isolating Cancer DNA March 18, 2026 8:17 AM - PR NewsWire Full Article List